Please login to the form below

Not currently logged in
Email:
Password:

Antiretroviral therapy

This page shows the latest Antiretroviral therapy news and features for those working in and with pharma, biotech and healthcare.

NHS England will make PrEP for HIV available in April

NHS England will make PrEP for HIV available in April

The PrEP Impact Trial is using Mylan's generic version of Gilead Sciences’ antiretroviral therapy Truvada (emtricitabine/tenofovir disoproxil) but is due to come to an end in October.

Latest news

  • Gilead drug reduces HIV viral reservoir, says researcher Gilead drug reduces HIV viral reservoir, says researcher

    suppression prior to starting antiretroviral therapy (ART). ... Stem cell transplants are high-risk procedures, so the treatment wouldn’t be suitable as a routine therapy for HIV-positive people.

  • FDA rejects ViiV’s long-acting monthly HIV injection FDA rejects ViiV’s long-acting monthly HIV injection

    ATLAS involved pateints who had been previously treated with long-acting antiretroviral therapy (ART), and showed that the combination injection matched standard therapy on viral suppression rates. ... Three patients treated with ViiV’s injectable (1%)

  • Dovato approval key for Glaxo in HIV treatment Dovato approval key for Glaxo in HIV treatment

    ViiV already have another two-in-one STR, Juluca (dolutegravir/rilpivirine), but this is only approved for HIV patients who have achieved viral suppression with another antiretroviral therapy. ... The HIV therapy market is also likely to be affected by

  • GSK, J&J say monthly injection keeps HIV controlled GSK, J&J say monthly injection keeps HIV controlled

    The long-acting antiretroviral therapy (ART) could mean that more patients adhere to the treatment regimen needed to suppress HIV, and avoid the risk of skipped doses that can help viral ... If approved, this two-drug regimen would give people living

  • GSK’s says depot HIV injection works over three years GSK’s says depot HIV injection works over three years

    Moreover, patients in a control arm receiving standard oral antiretroviral therapy (ART) who elected to swap over to the injectable regimen after 96 weeks did so without loss of viral suppression, ... combinations GSK is hoping will simplify HIV therapy

More from news
Approximately 1 fully matching, plus 42 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mind+Matter

We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...

Latest intelligence

Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....